These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 15781188

  • 1. Modeling aided design of potent glycogen phosphorylase inhibitors.
    Deng Q, Lu Z, Bohn J, Ellsworth KP, Myers RW, Geissler WM, Harris G, Willoughby CA, Chapman K, McKeever B, Mosley R.
    J Mol Graph Model; 2005 Apr; 23(5):457-64. PubMed ID: 15781188
    [Abstract] [Full Text] [Related]

  • 2. Discovering benzamide derivatives as glycogen phosphorylase inhibitors and their binding site at the enzyme.
    Chen L, Li H, Liu J, Zhang L, Liu H, Jiang H.
    Bioorg Med Chem; 2007 Nov 01; 15(21):6763-74. PubMed ID: 17719791
    [Abstract] [Full Text] [Related]

  • 3. Thermodynamic characterization of allosteric glycogen phosphorylase inhibitors.
    Anderka O, Loenze P, Klabunde T, Dreyer MK, Defossa E, Wendt KU, Schmoll D.
    Biochemistry; 2008 Apr 22; 47(16):4683-91. PubMed ID: 18373353
    [Abstract] [Full Text] [Related]

  • 4. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
    Kristiansen M, Andersen B, Iversen LF, Westergaard N.
    J Med Chem; 2004 Jul 01; 47(14):3537-45. PubMed ID: 15214781
    [Abstract] [Full Text] [Related]

  • 5. Crystallographic studies on acyl ureas, a new class of glycogen phosphorylase inhibitors, as potential antidiabetic drugs.
    Oikonomakos NG, Kosmopoulou MN, Chrysina ED, Leonidas DD, Kostas ID, Wendt KU, Klabunde T, Defossa E.
    Protein Sci; 2005 Jul 01; 14(7):1760-71. PubMed ID: 15987904
    [Abstract] [Full Text] [Related]

  • 6. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG, Somsák L.
    Curr Opin Investig Drugs; 2008 Apr 01; 9(4):379-95. PubMed ID: 18393105
    [Abstract] [Full Text] [Related]

  • 7. Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes.
    Klabunde T, Wendt KU, Kadereit D, Brachvogel V, Burger HJ, Herling AW, Oikonomakos NG, Kosmopoulou MN, Schmoll D, Sarubbi E, von Roedern E, Schönafinger K, Defossa E.
    J Med Chem; 2005 Oct 06; 48(20):6178-93. PubMed ID: 16190745
    [Abstract] [Full Text] [Related]

  • 8. Kinetic analysis and modelling of the allosteric behaviour of liver and muscle glycogen phosphorylases.
    Cuadri-Tomé C, Barón C, Jara-Pérez V, Parody-Morreale A, Martinez JC, Cámara-Artigas A.
    J Mol Recognit; 2006 Oct 06; 19(5):451-7. PubMed ID: 16691548
    [Abstract] [Full Text] [Related]

  • 9. Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding.
    Alexacou KM, Hayes JM, Tiraidis C, Zographos SE, Leonidas DD, Chrysina ED, Archontis G, Oikonomakos NG, Paul JV, Varghese B, Loganathan D.
    Proteins; 2008 May 15; 71(3):1307-23. PubMed ID: 18041758
    [Abstract] [Full Text] [Related]

  • 10. Glutathione-dependent reduction of arsenate by glycogen phosphorylase responsiveness to endogenous and xenobiotic inhibitors.
    Gregus Z, Németi B.
    Toxicol Sci; 2007 Nov 15; 100(1):44-53. PubMed ID: 17693424
    [Abstract] [Full Text] [Related]

  • 11. Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: comparison of chrysin and flavopiridol.
    Tsitsanou KE, Hayes JM, Keramioti M, Mamais M, Oikonomakos NG, Kato A, Leonidas DD, Zographos SE.
    Food Chem Toxicol; 2013 Nov 15; 61():14-27. PubMed ID: 23279842
    [Abstract] [Full Text] [Related]

  • 12. 1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modelling studies.
    Tsirkone VG, Tsoukala E, Lamprakis C, Manta S, Hayes JM, Skamnaki VT, Drakou C, Zographos SE, Komiotis D, Leonidas DD.
    Bioorg Med Chem; 2010 May 15; 18(10):3413-25. PubMed ID: 20430629
    [Abstract] [Full Text] [Related]

  • 13. N-(4-Substituted-benzoyl)-N'-(β-d-glucopyranosyl)ureas as inhibitors of glycogen phosphorylase: Synthesis and evaluation by kinetic, crystallographic, and molecular modelling methods.
    Nagy V, Felföldi N, Kónya B, Praly JP, Docsa T, Gergely P, Chrysina ED, Tiraidis C, Kosmopoulou MN, Alexacou KM, Konstantakaki M, Leonidas DD, Zographos SE, Oikonomakos NG, Kozmon S, Tvaroška I, Somsák L.
    Bioorg Med Chem; 2012 Mar 01; 20(5):1801-16. PubMed ID: 22325154
    [Abstract] [Full Text] [Related]

  • 14. Bioactivity of glycogen phosphorylase inhibitors that bind to the purine nucleoside site.
    Hampson LJ, Arden C, Agius L, Ganotidis M, Kosmopoulou MN, Tiraidis C, Elemes Y, Sakarellos C, Leonidas DD, Oikonomakos NG.
    Bioorg Med Chem; 2006 Dec 01; 14(23):7835-45. PubMed ID: 16908161
    [Abstract] [Full Text] [Related]

  • 15. The binding of β-d-glucopyranosyl-thiosemicarbazone derivatives to glycogen phosphorylase: A new class of inhibitors.
    Alexacou KM, Tenchiu Deleanu AC, Chrysina ED, Charavgi MD, Kostas ID, Zographos SE, Oikonomakos NG, Leonidas DD.
    Bioorg Med Chem; 2010 Nov 15; 18(22):7911-22. PubMed ID: 20947361
    [Abstract] [Full Text] [Related]

  • 16. 5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
    Wright SW, Rath VL, Genereux PE, Hageman DL, Levy CB, McClure LD, McCoid SC, McPherson RK, Schelhorn TM, Wilder DE, Zavadoski WJ, Gibbs EM, Treadway JL.
    Bioorg Med Chem Lett; 2005 Jan 17; 15(2):459-65. PubMed ID: 15603973
    [Abstract] [Full Text] [Related]

  • 17. Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme.
    Freeman S, Bartlett JB, Convey G, Hardern I, Teague JL, Loxham SJ, Allen JM, Poucher SM, Charles AD.
    Br J Pharmacol; 2006 Nov 17; 149(6):775-85. PubMed ID: 17016495
    [Abstract] [Full Text] [Related]

  • 18. Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors.
    Benltifa M, Hayes JM, Vidal S, Gueyrard D, Goekjian PG, Praly JP, Kizilis G, Tiraidis C, Alexacou KM, Chrysina ED, Zographos SE, Leonidas DD, Archontis G, Oikonomakos NG.
    Bioorg Med Chem; 2009 Oct 15; 17(20):7368-80. PubMed ID: 19781947
    [Abstract] [Full Text] [Related]

  • 19. 3'-axial CH2 OH substitution on glucopyranose does not increase glycogen phosphorylase inhibitory potency. QM/MM-PBSA calculations suggest why.
    Manta S, Xipnitou A, Kiritsis C, Kantsadi AL, Hayes JM, Skamnaki VT, Lamprakis C, Kontou M, Zoumpoulakis P, Zographos SE, Leonidas DD, Komiotis D.
    Chem Biol Drug Des; 2012 May 15; 79(5):663-73. PubMed ID: 22296957
    [Abstract] [Full Text] [Related]

  • 20. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ, Greenhaff PL, MacInnes A, Timmons JA.
    Diabetes; 2006 Jun 15; 55(6):1855-61. PubMed ID: 16731853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.